健脾补肾方联合化疗在大肠癌术后复发转移中的应用效果及对生存质量的影响研究
|
摘要
目的:探讨在大肠癌术后复发转移中,化疗、健脾补肾方联合应用的临床价值。方法:大肠癌术后复发转移患者(共80例)依照入院单双号随机分成两组(例数一致),其中,参照组接受化疗,治疗组与此同时另接受健脾补肾方治疗,对两组患者的治疗成效予以评价。结果:治疗组的疾病控制率(DCR)、总有效率(ORR)均显著高于参照组,差异具有统计学意义(P<0.05);两组治疗前的糖类抗原199(CA199)、癌胚抗原(CEA)对比,差异无统计学意义(P>0.05);治疗组治疗后的CA199、CEA均显著低于参照组,且差异有统计学意义(P<0.05);治疗组的生存质量显著优于参照组,差异具有统计学意义(P<0.05);治疗组的总不良反应发生率显著低于参照组(15.00%vs 47.50%),差异具有统计学意义(P<0.05)。结论:在大肠癌术后复发转移中,健脾补肾方联合化疗的应用效果突出,有助于患者不良反应的控制和生存质量的改善。
Objective:To explore the clinical value of combined application of chemotherapy andJianpi Bushen Recipe in recurrence and metastasis of colorectal cancer.Methods:Patients with recurrence and metastasis of colorectal cancer diagnosed(80 cases in total) were randomly divided into two groups according to the admission number(the number of cases was consistent). Among them, the reference group received chemotherapyand the treatment group received Jianpi Bushen Recipe at the same time. We evaluated the treatment effectiveness of two groups.Results:The disease control rate(DCR) and total effective rate(ORR) of the treatment group were significantly higher than those of the reference group.The difference was statistically significant(P<0.05).The two groups' pre-treatment carbohydrate antigen 199(CA199) and carcinoembryonic antigen(CEA) were not statistically significant(P>0.05). The CA199 and CEA in the treatment group were significantly lower than those of the reference group, and the difference was statistically significant(P<0.05). The quality of life of the treatment group was excellent. In the reference group, the difference was statistically significant(P<0.05).The incidence of total adverse reactions in the treatment group was significantly lower than that in the reference group(15.00% vs 47.50%)and the difference was statistically significant(P<0.05).Conclusion:In the postoperative recurrence and metastasis of colorectal cancer, the application of Jianpi Bushen Recipe combined with chemotherapy is outstanding, which is helpful for the control of adverse reactions and the improvement of quality of life.
Objective:To explore the clinical value of combined application of chemotherapy andJianpi Bushen Recipe in recurrence and metastasis of colorectal cancer.Methods:Patients with recurrence and metastasis of colorectal cancer diagnosed(80 cases in total) were randomly divided into two groups according to the admission number(the number of cases was consistent). Among them, the reference group received chemotherapyand the treatment group received Jianpi Bushen Recipe at the same time. We evaluated the treatment effectiveness of two groups.Results:The disease control rate(DCR) and total effective rate(ORR) of the treatment group were significantly higher than those of the reference group.The difference was statistically significant(P<0.05).The two groups' pre-treatment carbohydrate antigen 199(CA199) and carcinoembryonic antigen(CEA) were not statistically significant(P>0.05). The CA199 and CEA in the treatment group were significantly lower than those of the reference group, and the difference was statistically significant(P<0.05). The quality of life of the treatment group was excellent. In the reference group, the difference was statistically significant(P<0.05).The incidence of total adverse reactions in the treatment group was significantly lower than that in the reference group(15.00% vs 47.50%)and the difference was statistically significant(P<0.05).Conclusion:In the postoperative recurrence and metastasis of colorectal cancer, the application of Jianpi Bushen Recipe combined with chemotherapy is outstanding, which is helpful for the control of adverse reactions and the improvement of quality of life.
引文
[1] 郭凯波,严卿莹,阮善明,等.中医药联合化疗预防Ⅱ～Ⅲ期结直肠癌术后复发转移的Meta分析[J].广州中医药大学学报,2017,34(4):617-622.
[2] 薛建章,王瑞敏.中医药联合化疗对大肠癌根治术后复发、转移以及生存期的影响研究[J].中国现代药物应用,2016,10(5):259-260.
[3] 吴浩胥,裴海平.Ⅱ、Ⅲ期结肠癌根治术后患者肿瘤复发转移的影响因素分析[J].实用癌症杂志,2015,30(5):720-722.
[4] 穆守印.中西医结合治疗复发/转移性结直肠癌临床研究[J].中医学报,2016,31(5):639-641.
[5] 陈灏珠,林果为.实用内科学[M].13版.北京:人民卫生出版社,2009:2027-2030.
[6] 中华人民共和国卫生部.中药新药临床研究指导原则[S].北京:中国医药科技出版社,2002:361-364.
[7] Eisenhauer EA,Therasse P,Bogaerts J,et al.New response evaluation criteria in solid tumours:revised RECIST guideline(version 1.1)[J].Eur J Cancer,2009,45(2):228-247
[8] 刘斌,刘丽霞,臧爱民,等.健脾解毒方联合化疗治疗转移性大肠癌的有效性和安全性观察[J].中华中医药学刊,2016,34(5):1218-1220.
[9] 刘华,杨贵义.槐耳清膏对手术切除结肠癌后肿瘤复发及转移的影响及其机制研究[J].现代中西医结合杂志,2016,25(9):968-970.
[10] 王哲,秦宝丽,孙玉秀,等.复发转移大肠癌患者血清PTEN、COX2蛋白表达的研究[J].癌症进展,2017,15(3):283-286.
[11] 杨晓,蒋益兰.中医药预防大肠癌复发转移的研究进展[J].湖南中医杂志,2016,32(5):193-195.
[12] 孟钰,武秀杰,李志超.中西医结合治疗结直肠癌根治术后复发转移疗效观察[J].临床心身疾病杂志,2018,24(3):180-181.
[13] 史曦凯,程才,郭力硕,等.华蟾素防治大肠癌术后复发转移临床观察[J].深圳中西医结合杂志,2016,26(11):72-73.
[14] 王学中,季秀海.健脾补肾活血方改善大肠癌术后化疗毒副作用临床观察[J].新中医,2015,47(8):210-212.
[15] 王倩竹,江伟廷,李恒,等.健脾抑癌汤防治结直肠癌术后复发及癌转移的效果及作用分析[J].四川中医,2017,35(3):80-82.
[16] 展鹏远.健脾活血中药联合化疗治疗大肠癌术后患者临床观察[J].新中医,2017,49(4):116-118.
[17] 高文凯.疏肝健脾法预防大肠癌术后复发转移32例[J].北方药学,2015,12(6):26-27.
[18] 雷彩云,毛丹,丁陈陈,等.健脾解毒方联合化疗治疗大肠癌术后患者的临床观察[J].湖南中医药大学学报,2016,36(11):64-67.
[19] 卢冬雪,刘沈林.中医药防治结直肠癌术后复发转移的概况[J].世界中西医结合杂志,2017,12(11):1620-1623.
[20] 王华中,吴玉华,曹文,等.健脾益肾、化瘀解毒法联合化疗治疗老年结直肠癌术后30例临床观察[J].中医临床研究,2018,10(2):15-17.
[21] 王鲁英,王秋颖,唐金绍,等.结直肠癌肝转移患者术后的复发生存状况分析[J].实用癌症杂志,2015,30(7):1078-1080.
[22] 吴健瑜,杨海淦,陈育忠,等.健脾渗湿抑瘤法联合XELOX化疗治疗结肠癌根治术后疗效观察[J].新中医,2015,47(12):183-185.
[23] 杨尚真.祛邪胶囊减少Ⅱ、Ⅲ期结肠癌术后复发及转移效果研究[J].中医临床研究,2015,7(5):8-10.
[24] 张彦博,刘宣,季青,等.健脾解毒方联合化疗治疗转移性结直肠癌临床研究[J].中华中医药杂志,2015,30(6):2090-2093.
[25] 贺雪,殷佩浩.中医药治疗结直肠癌术后复发转移的研究进展[J].辽宁中医杂志,2017,44(9):2009-2012.
[2] 薛建章,王瑞敏.中医药联合化疗对大肠癌根治术后复发、转移以及生存期的影响研究[J].中国现代药物应用,2016,10(5):259-260.
[3] 吴浩胥,裴海平.Ⅱ、Ⅲ期结肠癌根治术后患者肿瘤复发转移的影响因素分析[J].实用癌症杂志,2015,30(5):720-722.
[4] 穆守印.中西医结合治疗复发/转移性结直肠癌临床研究[J].中医学报,2016,31(5):639-641.
[5] 陈灏珠,林果为.实用内科学[M].13版.北京:人民卫生出版社,2009:2027-2030.
[6] 中华人民共和国卫生部.中药新药临床研究指导原则[S].北京:中国医药科技出版社,2002:361-364.
[7] Eisenhauer EA,Therasse P,Bogaerts J,et al.New response evaluation criteria in solid tumours:revised RECIST guideline(version 1.1)[J].Eur J Cancer,2009,45(2):228-247
[8] 刘斌,刘丽霞,臧爱民,等.健脾解毒方联合化疗治疗转移性大肠癌的有效性和安全性观察[J].中华中医药学刊,2016,34(5):1218-1220.
[9] 刘华,杨贵义.槐耳清膏对手术切除结肠癌后肿瘤复发及转移的影响及其机制研究[J].现代中西医结合杂志,2016,25(9):968-970.
[10] 王哲,秦宝丽,孙玉秀,等.复发转移大肠癌患者血清PTEN、COX2蛋白表达的研究[J].癌症进展,2017,15(3):283-286.
[11] 杨晓,蒋益兰.中医药预防大肠癌复发转移的研究进展[J].湖南中医杂志,2016,32(5):193-195.
[12] 孟钰,武秀杰,李志超.中西医结合治疗结直肠癌根治术后复发转移疗效观察[J].临床心身疾病杂志,2018,24(3):180-181.
[13] 史曦凯,程才,郭力硕,等.华蟾素防治大肠癌术后复发转移临床观察[J].深圳中西医结合杂志,2016,26(11):72-73.
[14] 王学中,季秀海.健脾补肾活血方改善大肠癌术后化疗毒副作用临床观察[J].新中医,2015,47(8):210-212.
[15] 王倩竹,江伟廷,李恒,等.健脾抑癌汤防治结直肠癌术后复发及癌转移的效果及作用分析[J].四川中医,2017,35(3):80-82.
[16] 展鹏远.健脾活血中药联合化疗治疗大肠癌术后患者临床观察[J].新中医,2017,49(4):116-118.
[17] 高文凯.疏肝健脾法预防大肠癌术后复发转移32例[J].北方药学,2015,12(6):26-27.
[18] 雷彩云,毛丹,丁陈陈,等.健脾解毒方联合化疗治疗大肠癌术后患者的临床观察[J].湖南中医药大学学报,2016,36(11):64-67.
[19] 卢冬雪,刘沈林.中医药防治结直肠癌术后复发转移的概况[J].世界中西医结合杂志,2017,12(11):1620-1623.
[20] 王华中,吴玉华,曹文,等.健脾益肾、化瘀解毒法联合化疗治疗老年结直肠癌术后30例临床观察[J].中医临床研究,2018,10(2):15-17.
[21] 王鲁英,王秋颖,唐金绍,等.结直肠癌肝转移患者术后的复发生存状况分析[J].实用癌症杂志,2015,30(7):1078-1080.
[22] 吴健瑜,杨海淦,陈育忠,等.健脾渗湿抑瘤法联合XELOX化疗治疗结肠癌根治术后疗效观察[J].新中医,2015,47(12):183-185.
[23] 杨尚真.祛邪胶囊减少Ⅱ、Ⅲ期结肠癌术后复发及转移效果研究[J].中医临床研究,2015,7(5):8-10.
[24] 张彦博,刘宣,季青,等.健脾解毒方联合化疗治疗转移性结直肠癌临床研究[J].中华中医药杂志,2015,30(6):2090-2093.
[25] 贺雪,殷佩浩.中医药治疗结直肠癌术后复发转移的研究进展[J].辽宁中医杂志,2017,44(9):2009-2012.